Johnson & Johnson (Israel)

Recent papers from Johnson & Johnson (Israel)

1. Associations Between Clinical Characteristics and Magnetic Resonance Imaging of the Sacroiliac Joints and Spine: Exploratory Analysis of the Phase 4, Randomized, Placebo-Controlled STAR StudyJournal of Psoriasis and Psoriatic Arthritis · 2026
2. CASyM: Chemotype Annotation through Synthesis MappingJournal of Chemical Information and Modeling · 2026
3. Understanding the Lived Experience of Fetal and Neonatal Alloimmune Thrombocytopenia: A Qualitative StudyAmerican Journal of Perinatology Reports · 2026
4. Teclistamab and Daratumumab Immune-Based Doublet Therapy for Relapsed/Refractory Multiple Myeloma: the TRIMM-2 StudyBlood Advances · 2026
5. Real-world treatment patterns and outcomes of patients treated with commercial chimeric antigen receptor T-cell therapy for relapsed/refractory multiple myelomaCurrent Medical Research and Opinion · 2026
6. Vaccine Ligand Binding Assay DevelopmentBioanalysis · 2026
7. Patient characteristics, treatment patterns and clinical response in patients with treatment resistant depression starting a new treatment in the clinical setting: a multicenter, observational study in PortugalFrontiers in Psychiatry · 2026
8. Treatment patterns and outcomes in proximal humerus fracture management: a claims-based retrospective analysis of real-world US patient dataExpert Review of Pharmacoeconomics & Outcomes Research · 2026
9. Characteristics of Real-World Patients with Psoriasis Receiving Guselkumab or Interleukin-17 Inhibitors: Data from the Psoriasis Longitudinal Assessment and Registry (PSOLAR)Journal of Psoriasis and Psoriatic Arthritis · 2026
10. Host Cell Protein Challenges in Antibody Processing: Insights Into Persistence and Mitigation StrategiesBiotechnology and Bioengineering · 2026
11. Smoldering multiple myeloma: a multi-country mixed-methods study on disease perceptions and patient treatment preferencesFuture Oncology · 2026
12. Efficacy and Safety of Teclistamab in Relapsed/Refractory Multiple Myeloma: 2‐Year Follow‐Up From MajesTEC‐1 China CohorteJHaem · 2026
13. The State of Motion: Demographic and Representational Consequences of Motion-Based Exclusion in FMRI2026
14. Setting expectations for current and future directions of native mass spectrometry in the biopharmaceutical industrymAbs · 2026
15. Effectiveness of daratumumab plus bortezomib, lenalidomide, and dexamethasone (DVRd) versus VRd for transplant-eligible newly diagnosed multiple myelomaFuture Oncology · 2026
16. Identification of a Class of Novel, Selective, Structurally Distinct GluN2A Negative Allosteric Modulators Through Virtual ScreeningChemMedChem · 2026
17. Symposium Report: Stakeholders' Perspectives on Phase 1 Trials in Japanese Prior to Multi‐Regional Clinical Trials and Future PathwaysClinical Pharmacology & Therapeutics · 2026
18. Episodic and semantic memory contributions to imagination and creativityMemory · 2026
19. Trajectory of response to esketamine nasal spray for treatment resistant depression: findings from ESCAPE-TRDEuropean Psychiatry · 2026
20. Quantifying Transporter Activity: An Absolute Scaling Approach Using DigoxinMolecular Pharmaceutics · 2026